Drugs like Ozempic, Mounjaro and Saxenda have swept the globe since emerging on the market late last decade, and an estimated 20,000 Australians currently use the drugs for weight loss.

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

A new study conducted by researchers from the University of Eastern Finland the Karolinska Institutet explored the ways that ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

The company behind popular weight-loss drugs failed to disclose even more ... Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose ...

For many struggling with weight management, new medications like Wegovy, Mounjaro, and Saxenda have been seen as ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Recent research reveals that weight-loss injections reduce the risk of 42 health conditions in people with diabetes, potentially paving the way for broader treatments.